|
Resistance prevalence for selected drug-bug pairs by patient type, U.S. 1999–2002 |
||||
| unit: % |
||||
|
|
||||
| Pair |
Bacterium (resistant to) → drug |
ICU patients |
non-ICU inpatients |
Outpatients |
|
|
||||
| A |
PAE → Ciprofloxacin/ofloxacin |
32 |
25 |
23 |
| B |
PAE → Levofloxacin |
37 |
28 |
25 |
| C |
PAE → Imipenem |
18 |
12 |
9 |
| D |
PAE → Ceftazidime |
13 |
8 |
5 |
| E |
PAE → Piperacillin |
16 |
11 |
6 |
| F |
SAU → Methicillin |
47 |
38 |
23 |
| G |
Enterococcus spp → Vancomycin |
13 |
11 |
4 |
| H |
ECO → Cef3* |
1 |
1 |
0 |
| I |
ECO → Quinolone** |
5 |
4 |
2 |
| J |
KPN → Cef3 |
6 |
5 |
2 |
| K |
Enterobacter spp → Cef3 |
26 |
21 |
10 |
| L |
Enterobacter spp → Carbapenum |
1 |
1 |
1 |
| M |
CNS → Methicillin |
75 |
63 |
46 |
| N |
Pneumococcus → Penicillin |
18 |
17 |
17 |
| O |
Pneumococcus → Cef3 |
7 |
8 |
6 |
| Mean |
21 |
17 |
12 |
|
|
*Cef3 (3rd generation cephalosporin) = ceftazidime, cefotaxime or ceftriaxone; **Quinolone = ciprofloxacin, ofloxacin or levofloxacin. | ||||
Zhang et al. Globalization and Health 2006 2:6 doi:10.1186/1744-8603-2-6 |
||||